These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37823722)

  • 1. Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.
    Calvi A; Mendelsohn Z; Hamed W; Chard D; Tur C; Stutters J; MacManus D; Kanber B; Wheeler-Kingshott CAMG; Barkhof F; Prados F
    Eur J Neurol; 2024 Jan; 31(1):e16092. PubMed ID: 37823722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
    Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Preziosa P; Pagani E; Moiola L; Rodegher M; Filippi M; Rocca MA
    Mult Scler; 2021 Sep; 27(10):1520-1532. PubMed ID: 33183125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Calvi A; Carrasco FP; Tur C; Chard DT; Stutters J; De Angelis F; John N; Williams T; Doshi A; Samson RS; MacManus D; Gandini Wheeler-Kingshott CA; Ciccarelli O; Chataway J; Barkhof F;
    Neurology; 2022 Apr; 98(17):e1783-e1793. PubMed ID: 35277438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
    Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis.
    Calvi A; Clarke MA; Prados F; Chard D; Ciccarelli O; Alberich M; Pareto D; Rodríguez Barranco M; Sastre-Garriga J; Tur C; Rovira A; Barkhof F
    Mult Scler; 2023 Mar; 29(3):352-362. PubMed ID: 36515487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL; Elliott C; Martin EC; Hyvert Y; Tomic D; Montalban X
    Neurology; 2024 Mar; 102(5):e208058. PubMed ID: 38335474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal myelin content measures of slowly expanding lesions using 7T MRI in multiple sclerosis.
    Huerta MM; Conway DS; Planchon SM; Thoomukuntla B; Se-Hong O; Sakaie KE; Ontaneda D; Nakamura K
    J Neuroimaging; 2024; 34(4):451-458. PubMed ID: 38778455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis.
    Elliott C; Rudko DA; Arnold DL; Fetco D; Elkady AM; Araujo D; Zhu B; Gafson A; Tian Z; Belachew S; Bradley DP; Fisher E
    Mult Scler; 2023 May; 29(6):680-690. PubMed ID: 37036134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lesion activity and disability progression in secondary progressive multiple sclerosis.
    Beynon V; George IC; Elliott C; Arnold DL; Ke J; Chen H; Zhu L; Ke C; Giovannoni G; Scaramozza M; Campbell N; Bradley DP; Franchimont N; Gafson A; Belachew S
    BMJ Neurol Open; 2022; 4(1):e000240. PubMed ID: 35720980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
    Zivadinov R; Medin J; Khan N; Korn JR; Bergsland N; Dwyer MG; Chitnis T; Naismith RT; Alvarez E; Kinkel P; Cohan S; Hunter SF; Silva D; Weinstock-Guttman B;
    J Neuroimaging; 2018 Jul; 28(4):399-405. PubMed ID: 29749661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
    Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
    J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.
    Kolind S; Seddigh A; Combes A; Russell-Schulz B; Tam R; Yogendrakumar V; Deoni S; Sibtain NA; Traboulsee A; Williams SC; Barker GJ; Brex PA
    Neuroimage Clin; 2015; 9():574-80. PubMed ID: 26594633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
    Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.